Stablecoin Development Corporation SDEV

Stablecoin Development Corp is an on-chain holding company focused on long-duration participation in protocol-aligned digital asset ecosystems. The Company's initial digital asset focus is the Sky protocol ecosystem, with SKY as its core holding. Through staking and other on-chain activities, the Company seeks to generate protocol-level economic returns while maintaining rigorous governance and risk management oversight.

• GlobeNewswire Inc. 3 ago

  SDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly Novabay Pharmaceuticals, Inc.) Stockholders

  Abbott Cooper PLLC is investigating potential fiduciary duty breaches by the board of directors of Stablecoin Development Corporation (formerly NovaBay Pharmaceuticals, Inc.). The investigation targets stockholders who continuously held shares since prior to August 19, 2025. Similar investigations are also underway for Kalaris Therapeutics (formerly AlloVir) and Abundia Global Impact Group (formerly Houston American Energy Corp.).

  

• GlobeNewswire Inc. 8 jul

  AGIG: Abbott Cooper PLLC Announces Investigation on Behalf of Abundia Global Impact Group, Inc. (Formerly Houston American Energy Corp.) Stockholders

  Abbott Cooper PLLC has announced investigations into potential fiduciary duty violations and wrongdoing by the boards of directors of three companies: Abundia Global Impact Group, Inc. (formerly Houston American Energy Corp.), Estrella Immunopharma, Inc., and Stablecoin Development Corporation (formerly NovaBay Pharmaceuticals, Inc.). The law firm is seeking stockholders who held shares continuously since July 1, 2025, or earlier to join the investigations on a contingency fee basis.

  

• GlobeNewswire Inc. 17 jun

  SDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly NovaBay Pharmaceuticals, Inc.) Stockholders

  Abbott Cooper PLLC is investigating potential fiduciary duty violations by the Board of Stablecoin Development Corporation (formerly NovaBay Pharmaceuticals, Inc.) in connection with a private placement of preferred stock. The investigation targets stockholders who held shares prior to August 19, 2025.